Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Nature Communications, 7, 1, S. 12008-
- Ereignis
-
Veröffentlichung
- (wo)
-
Augsburg
- (wer)
-
Universität Augsburg
- (wann)
-
2016
- Ereignis
-
Veröffentlichung
- (wer)
-
Springer Science and Business Media LLC
- (wann)
-
2016
- Urheber
-
Ulz, Peter
Belic, Jelena
Graf, Ricarda
Auer, Martina
Lafer, Ingrid
Fischereder, Katja
Webersinke, Gerald
Pummer, Karl
Augustin, Herbert
Pichler, Martin
Hoefler, Gerald
Bauernhofer, Thomas
Geigl, Jochen B.
Heitzer, Ellen
Speicher, Michael
- DOI
-
10.1038/ncomms12008
- URN
-
urn:nbn:de:bvb:384-opus4-1028483
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ulz, Peter
- Belic, Jelena
- Graf, Ricarda
- Auer, Martina
- Lafer, Ingrid
- Fischereder, Katja
- Webersinke, Gerald
- Pummer, Karl
- Augustin, Herbert
- Pichler, Martin
- Hoefler, Gerald
- Bauernhofer, Thomas
- Geigl, Jochen B.
- Heitzer, Ellen
- Speicher, Michael
- Universität Augsburg
- Springer Science and Business Media LLC
Entstanden
- 2016
Ähnliche Objekte (12)
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
Best of ASCO 2022: bladder cancer
High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
Inflammation, phagocytosis and cancer: another step in the CD47 act
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancer — the more specific, the better?
Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition
Involvement of the long noncoding RNA NEAT1 in carcinogenesis
RNA-binding proteins as important regulators of long non-coding RNAs in cancer
Multi-omics in prognosis of hepatocellular carcinoma
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
Best of ASCO 2022: bladder cancer
High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
Inflammation, phagocytosis and cancer: another step in the CD47 act
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancer — the more specific, the better?
Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition
Involvement of the long noncoding RNA NEAT1 in carcinogenesis
RNA-binding proteins as important regulators of long non-coding RNAs in cancer
Multi-omics in prognosis of hepatocellular carcinoma
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
Best of ASCO 2022: bladder cancer
High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
Inflammation, phagocytosis and cancer: another step in the CD47 act
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancer — the more specific, the better?
Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition
Involvement of the long noncoding RNA NEAT1 in carcinogenesis
RNA-binding proteins as important regulators of long non-coding RNAs in cancer